Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients
第一作者机构：[1]Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714)：
Zhang L.,Lu S.,Dechaphunkul A.,et al.Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients[J].ANNALS OF ONCOLOGY.2017,28:-.doi:10.1093/annonc/mdx676.
APA：
Zhang, L.,Lu, S.,Dechaphunkul, A.,Chessari, S.,Lanzarotti, C....&Aapro, M..(2017).Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients.ANNALS OF ONCOLOGY,28,
MLA：
Zhang, L.,et al."Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients".ANNALS OF ONCOLOGY 28.(2017):-
医学